Ephedrine plus caffeine causes age-dependent cardiovascular responses in Fischer 344 rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 5 57-5, 2005, Pages

  Howden, Reuben ^a   Hanlon, Paul R ^a   Petranka, John G ^a   Kleeberger, Steven ^a   Bucher, John ^a   Dunnick, June ^a   Nyska, Abraham ^a   Murphy, Elizabeth ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cardiac toxicity; ECG; Heart rate; Hyperthermia

Indexed keywords

CAFFEINE; EPHEDRINE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BODY TEMPERATURE; CARDIOTOXICITY; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG FATALITY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART RATE; HISTOPATHOLOGY; HYPERTHERMIA; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RAT; RAT STRAIN;

AGE FACTORS; ANIMALS; BODY TEMPERATURE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG SYNERGISM; ELECTROCARDIOGRAPHY; EPHEDRINE; FEVER; HEART RATE; MALE; PAPILLARY MUSCLES; RATS; RATS, INBRED F344;

EID: 18044367763     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01164.2004     Document Type: Article

References (18)

1. Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, Strauss R, and Meredith T. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 26: 593-604, 2002.
2. Foxford RJ, Sahlas DJ, and Wingfield KA. Vasospasm-induced stroke in a varsity athlete secondary to ephedrine ingestion. Clin J Sport Med 13: 183-185, 2003.
3. Fredholm B. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 76: 93-101, 1997.
4. Haller CA and Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343: 1833-1838, 2000.
5. Kuo CS, Munakata K, Reddy CP, and Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 67: 1356-1367, 1983.
6. Lustik SJ, Chhibber AK, van Vliet M, and Pomerantz RM. Ephedrine-induced coronary artery vasospasm in a patient with prior cocaine use. Anesth Analg 84: 931-933, 1997.
7. McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, and White CM. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA 291: 216-221, 2004.
8. McFalls EO, Murad B, Her D, Liow JS, Kelly R, Marx B, Sikora J, and Ward HB. Repetitive supply-demand ischemia with dobutamine increases glucose uptake in postischemic and remote myocardium. J Nucl Med 44: 85-91, 2003.
9. Mills EM, Banks ML, Sprague JE, and Finkel T. Pharmacology: uncoupling the agony from ecstasy. Nature 426: 403-404, 2003.
10. Naik SD and Freudenberger RS. Ephedra-associated cardiomyopathy. Ann Pharmacother 38: 400-403, 2004.
11. Rezkalla SH, Mesa J, Sharma P, and Kloner RA. Myocardial infarction temporally related to ephedra - a possible role for the coronary microcirculation. WMJ 101: 64-66, 2002.
12. Richardt G, Waas W, Kranzhofer R, Mayer E, and Schomig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res 61: 117-123, 1987.
13. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 17: 291-306, 1985.
14. Samennk D, Link MS, Homoud MK, Contreras R, Theoharides TC, Wang PJ, Estes NA III, and Theohardes TC. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 77: 12-16, 2002.
15. Schrader J, Baumann G, and Gerlach E. Adenosine as inhibitor of myocardial effects of catecholamines. Pflügers Arch 372: 29-35, 1977.
16. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, and Gagne J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 289: 1537-1545, 2003.
17. Tong H, Chen W, London RE, Murphy E, and Steenbergen C. Preconditioning enhanced glucose uptake is mediated by p38 MAP kinase not by phosphatidylinositol 3-kinase. J Biol Chem 275: 11981-11986, 2000.
18. White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, and Estes M. Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol 37: 116-122, 1997.